Skip to main content

Table 3 Work Productivity and Activity Impairment Questionnaire - Rheumatoid Arthritis (WPAI-RA): impairment of regular activities among all patients at baseline and least-squares mean change from baseline at week 24 and at week 52

From: Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

WPAI-RA question administered to all patientsa
  Baseline, Mean (SD) Week 24, LSM (95% CI) Week 52, LSM (95% CI)
  MTX (N = 210) Baricitinib 4 mg (N = 159) Baricitinib 4 mg + MTX (N = 215) MTX (N = 210) Baricitinib 4 mg (N = 159) Baricitinib 4 mg + MTX (N = 215) MTX (N = 210) Baricitinib 4 mg (N = 159) Baricitinib 4 mg + MTX (N = 215)
Percent activity impairment due to RA 61 (26) 62 (25) 59 (25) − 25 (− 29, − 22) − 37 (− 40, − 33)*** − 33 (− 37, − 30)*** − 29 (− 32, −25) − 35 (− 38, − 31)* − 38 (− 42, − 35)***
  1. CI confidence interval, LSM least-squares mean, MTX methotrexate, RA rheumatoid arthritis
  2. aData are presented as mean (standard deviation) unless stated otherwise
  3. *p ≤ 0.05; ***p ≤ 0.001 vs. MTX